News
UNCY
1.135
+1.34%
0.015
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
TipRanks · 3d ago
Weekly Report: what happened at UNCY last week (0422-0426)?
Weekly Report · 3d ago
Unicycive Therapeutics Inc: Other definitive proxy statementsOpen document
Press release · 5d ago
Weekly Report: what happened at UNCY last week (0415-0419)?
Weekly Report · 04/22 11:56
Unicycive Therapeutics Price Target Maintained With a $3.00/Share by Benchmark
Dow Jones · 04/15 15:10
Benchmark Reiterates Speculative Buy on Unicycive Therapeutics, Maintains $3 Price Target
Benzinga · 04/15 15:00
Weekly Report: what happened at UNCY last week (0408-0412)?
Weekly Report · 04/15 11:46
Buy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial Positioning
TipRanks · 04/11 19:05
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Unicycive Therapeutics, Inc. Is a clinical-stage biotechnology company developing therapies for patients with kidney disease. Shalabh Gupta, M.D., will present a company update at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024.
Barchart · 04/10 06:03
Weekly Report: what happened at UNCY last week (0401-0405)?
Weekly Report · 04/08 11:52
Unicycive Therapeutics Price Target Announced at $9.00/Share by Piper Sandler
Dow Jones · 04/04 11:13
Unicycive Therapeutics Initiated at Overweight by Piper Sandler
Dow Jones · 04/04 11:13
Unicycive Therapeutics: A Strong Buy on OLC’s Potential to Revolutionize Hyperphosphatemia Treatment in CKD
TipRanks · 04/04 09:05
Weekly Report: what happened at UNCY last week (0325-0329)?
Weekly Report · 04/01 11:49
CORRECTION: On Friday, Unicycive Therapeutics Reported Q4 EPS Of $(0.22), Which Missed $(0.17) Estimate
Benzinga · 04/01 11:04
Unicycive Therapeutics Price Target Maintained With a $4.50/Share by HC Wainwright & Co.
Dow Jones · 04/01 10:26
Buy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial Footing
TipRanks · 04/01 10:25
Unicycive Therapeutics Q4 EPS $(0.35) Misses $(0.17) Estimate
Benzinga · 03/29 04:53
UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023
Unicycive Therapeutics reported earnings per share of -35 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -17 cents. UnicycIVE Therapeutic reported results for the last quarter of 2013.
Investorplace · 03/29 02:53
Unicycive Therapeutics Inc: Annual report
Press release · 03/28 22:08
More
Webull provides a variety of real-time UNCY stock news. You can receive the latest news about Unicycive Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.